In a significant move within the pharmaceutical industry, CEO Michael Castagna has parted with a substantial number of shares in MannKind Corp (NASDAQ:MNKD).
DANBURY, Conn. DANBURY, Conn. MannKind Corp. on Tuesday reported third-quarter profit of $1.7 million. On a per-share basis, the Danbury, Connecticut-based company said it had profit.
Danbury-headquartered MannKind Corp. announced the U.S. Patent and Trademark Office issued a new patent (No. 11,793,808) covering the company’s clofazimine inhalation suspension (MNKD-101), which is under development for the potential treatment of nontuberculous mycobacterial (NTM) lung disease.